Lung cancer is a leading cause of death from cancer among men worldwide. In United States, 5-years survival rate of lung cancer is only 15%. In Bangladesh lung cancer is the commonest male cancer and accounts for 28.39% of all cancer patients (1, 2) . The two main histo-pathologic categories of lung cancer are non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). The majority of them is NSCLC, comprises 87% of all lung cancers. Metastatic involvement of mediastinal lymph nodes is a very common phenomenon in lung cancer. The status of regional lymph node is an important prognostic factor. Prognosis is also largely depended on the early diagnosis and precise staging of the disease. The treatment planning depends on tumor stage (3). Here we discuss about the common pitfalls of mediastinal adenopathy in lung cancer and relative merits of 2-(fluorine -18) fluoro-2 deoxy-D-glucose (18F FDG) positron emission tomography (PET), magnetic resonance imaging (MRI) imaging and computed tomography (CT).
The conventional methods for mediastinal staging include computed tomography (CT), magnetic resonance imaging (MRI) and mediastinoscopy with various biopsy procedures. Compared to the invasive procedures the noninvasive imaging modalities CT and MRI are lack of sensitivity and specificity for accurate meditational nodal staging in patients with lung cancer. However, biopsy procedures are inconvenient and potentially risky (6, 7) .
CT is the most widely available and commonly used imaging technique to assess intra-and extra-thoracic metastases. However, CT has been shown to have limited abilities when used as the sole modality in evaluating the mediastinum for metastases. Evaluation on conventional CT imaging is based upon size. Dwamena et al performed a meta-analysis of 14 PET studies for staging mediastinal adenopathy and found an overall sensitivity of 79% and an overall specificity of 91%. Accuracy was 92%, positive predictive value was 90% and negative predictive value was 93%. This is clearly superior to CT which has an overall reported sensitivity and specificity of 62% and 73%, respectively. PET staging of mediastinal nodes approaches mediastinoscopy, which has reported sensitivity between 72% to 94%. Results of the PET exam can also be used to more accurately guide mediastinal exploration with improve yield from preoperative mediastinal lymph node sampling (9).
The PET-CT is an integral part in quality management of lung cancer patients in developed countries. By integrating functional and anatomic data, PET-CT improves the N staging compared with PET or CT alone. Studies demonstrated increased sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET-CT for detecting metastatic lymph nodes of, respectively, 73%, 91%, 71%, 90%, and 86% versus 83%, 81%, 71%, 89%, 82% of PET alone and 74%, 73%, 52%, 88%, 73% of CT alone (10, 11) . The improved sensitivity of PET-CT may leads to greater number of false positive cases and reduced specificity. The number of false positive exams can be decreased by applying criteria regarding the attenuation density of the lymph node into image analysis. Lymph nodes with tracer uptake greater than mediastinal blood pool activity, but showing high attenuation on CT are considered by some authors to be benign. 
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Clinicians must understand the details set forth in the TNM classification system and be familiar with the changes in the 7th edition, which attempts to better correlate disease with prognostic value and treatment strategy. By recognizing the relevant radiologic appearances of staging of the disease with the TNM classification system, and being familiar with potential imaging pitfalls, nuclear radiologist or medicine physician can make an important contribution to treatment and outcome in lung cancer patients.
